Four Peptides, One Long Question About Aging Well

The short version

Youth Lab Peptides is a reading room, not a store. It gathers what the published research literature actually says about four peptides that keep coming up in conversations about healthspan — living well for longer, not just living longer — and cellular aging: BPC-157, NAD+, semaglutide, and Thymosin Alpha-1.

A peptide is just a short chain of amino acids, the building blocks of protein — some occur naturally in the body, others are made in a lab to mimic or support a natural process. These four sit at very different points on the science-to-shelf spectrum. NAD+ is a coenzyme every cell already makes and uses; semaglutide is an FDA-approved prescription drug; BPC-157 and Thymosin Alpha-1 are research peptides, one still investigational in the United States, the other approved as a medicine abroad.

This desk does one job: it says, in plain language and with citations, what each peptide was actually studied for, in which population, and how far that evidence honestly reaches. It sells nothing, gives no medical advice, and never lists a human dose outside the context of a cited study.

What are research peptides?

Peptides are short chains of amino acids — the same building blocks that make up every protein in the body, just far shorter. Some, like NAD+ precursors, are metabolites the body already produces constantly. Others, like BPC-157 and Thymosin Alpha-1, are synthetic sequences studied for specific reparative or immune actions. Semaglutide belongs to a fourth category entirely: an engineered analogue of a natural gut hormone, chemically modified for a long enough half-life to be dosed weekly, and formally approved as a prescription medicine.

Regulatory status varies sharply across the four. Semaglutide is FDA-approved for defined indications and available only by prescription. NAD+ and its common precursors (NMN, NR) are sold as dietary supplements, though the FDA has separately challenged NMN's supplement status. Thymosin Alpha-1 (thymalfasin) is an approved drug in more than 35 countries but carries no US marketing approval. BPC-157 has never been approved anywhere and is sold strictly as a research chemical, not for human consumption. Whenever this site reports a dose, it reports the dose used in a specific cited study — never as a suggestion for a reader to follow.

Healthspan and cellular-aging research across classes

These four compounds do not share a drug class, a mechanism, or even a regulatory category — what they share is that each has become part of the conversation about healthspan and cellular-aging research: not simply extending lifespan, but preserving the tissue repair, metabolic regulation, and immune competence that tend to decline with age.

NAD+ is arguably the most direct entry point: it is the cell's central redox coenzyme, and its measurable decline with age is one of the more consistently observed findings in aging biology, which is why boosting it with precursors like NMN and NR has become a major research thread ^[9]. BPC-157 enters from the tissue-repair side — a peptide whose reported pro-angiogenic and cytoprotective effects in animal models are the reason it is discussed in the context of recovery and regeneration, even though the human evidence remains thin. Semaglutide enters from metabolic regulation: beyond its approved weight-management and diabetes indications, its cardiovascular- and kidney-protective trial data connect it to the broader question of healthy metabolic aging. Thymosin Alpha-1 enters from immune resilience — thymic output and immune competence decline with age (a process called immunosenescence), and Tα1 is one of the few peptides with decades of human safety data in immune-restoration contexts.

Read individually, each page covers one compound on its own terms. Read together, they sketch four different angles on the same underlying question: what does it mean, biologically, to age well? Compare the four side by side.

A note on how this desk reads the literature

Youth Lab Peptides is a cross-referenced literature digest, not an advocacy site. Each compound page cites its claims by number against a single shared references list that aggregates every source across all four. The four compounds carry very different depths of human evidence — semaglutide has multi-thousand-participant randomized trials behind it; NAD+ precursor trials number in the dozens to low hundreds of participants; BPC-157's human record is three small pilot studies; Thymosin Alpha-1 has decades of use abroad but a null result in its largest recent trial. This desk says so plainly in each case rather than treating the four as evidentially interchangeable. Where a real-world or community-reported effect appears, it is explicitly labeled anecdotal, not clinical evidence, and never given alongside a dose.